-
Eli Lilly’s Oral Weight-Loss Medication Receives FDA Approval
The FDA has approved Eli Lilly’s new weight-loss pill, offering patients an oral alternative to injectable GLP-1 therapies for weight management.
-
Kither Biotech Announces Successful Completion of Phase 1 Clinical Trial for Novel Peptide Therapy
Kither Biotech has successfully completed a Phase 1 clinical trial for its peptide-based therapeutic candidate, marking a key milestone in the company’s mission to develop new treatments for respiratory disease.
-
FDA Signals Potential Support for Peptide Therapeutics Under New Leadership
Reports suggest the FDA under new leadership may take a more favorable stance toward peptide-based treatments, potentially opening doors for expanded research and development in this growing therapeutic category.
-
Lilly’s Triple-Acting Obesity Peptide Meets Key Goal in Phase 3 Trial
Eli Lilly announced its investigational triple-hormone-receptor obesity drug achieved its primary goal in a Phase 3 study, marking another step forward for next-generation weight management therapies.
-
Understanding Peptides: How GLP-1s and Insulin Are Helping Patients Today
A new patient-education overview from NewYork-Presbyterian explains how peptide-based therapies like GLP-1 medications and insulin are already improving health outcomes for millions.
-
Expanding Access: New Online Education Programs Help Medical Providers Master Peptide Therapies
New online training programs are helping medical providers build a deeper, more structured understanding of peptide therapies, supporting safer and more informed clinical use.
-
FDA Advisory Panel Gives Green Light to Six Peptides for Compounding Use
An FDA advisory panel has voted to support the inclusion of six peptides on a list used by compounding pharmacies, a step that could expand patient access to these therapies.
-
San Diego Biotech Deal Brings Up to $100M Per Target to Peptide Drug Discovery
Aizen has secured a partnership potentially worth up to $100 million per target, fueling further research and development into peptide-based therapeutics.
-
FDA Eases Restrictions on Six Peptides, Expanding Access for Researchers and Consumers
The FDA has relaxed restrictions on six peptide compounds, potentially broadening access for research and compounding use. Here’s what the change means for the peptide community.
-
FDA Advisory Panel Gives Green Light to Six Peptides for Compounding
An FDA expert panel has voiced support for allowing six specific peptides to be compounded, a step that could expand patient access to these therapies through licensed compounding pharmacies.